{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:10:32Z","timestamp":1782371432891,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":5668,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1111\/j.1538-7836.2007.02526.x","type":"journal-article","created":{"date-parts":[[2007,5,26]],"date-time":"2007-05-26T11:32:24Z","timestamp":1180179144000},"page":"1237-1242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis"],"prefix":"10.1016","volume":"5","author":[{"given":"W.","family":"WIENEN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010M.","family":"STASSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"PRIEPKE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.J.","family":"RIES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"HAUEL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0010","series-title":"Blood: Principles and Practice of Hematology","first-page":"949","article-title":"The hemostatic system","author":"Lind","year":"1995"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0015","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","article-title":"Direct thrombin inhibitors","volume":"353","author":"Di Nisio","year":"2005","journal-title":"New Engl J Med"},{"issue":"Suppl.","key":"10.1111\/j.1538-7836.2007.02526.x_bb0020","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low\u2010molecular\u2010weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"1","author":"Hirsh","year":"2001","journal-title":"Chest"},{"issue":"Suppl.","key":"10.1111\/j.1538-7836.2007.02526.x_bb0025","first-page":"8S","article-title":"Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range","volume":"1","author":"Hirsh","year":"2003","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0030","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Int Med"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0049-3848(98)00192-3","article-title":"Synthetic inhibitors of thrombin and factor Xa: From bench to bedside","volume":"93","author":"Hauptmann","year":"1999","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2006.06134.x","article-title":"The status of new anticoagulants","volume":"134","author":"Bates","year":"2006","journal-title":"Brit J Haematol"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0038-1648875","article-title":"Effects of the synthetic thrombin inhibitor argatroban on fibrin\u2010 or clot\u2010incorporated thrombin: comparison with heparin and recombinant hirudin","volume":"72","author":"Berry","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0050","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1073\/pnas.86.10.3619","article-title":"Fibrin monomer protects thrombin from inactivation by heparin\u2010antithrombin III: implications for heparin therapy","volume":"86","author":"Hogg","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot\u2010bound thrombin is protected from inhibition by heparin\u2010antithrombin III but is susceptible to inactivation by antithrombin III\u2010independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0060","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2796.2003.01225.x","article-title":"Oral direct thrombin inhibitors in clinical development","volume":"254","author":"Gustafsson","year":"2003","journal-title":"J Int Med"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0065","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrd1466","article-title":"A new oral anticoagulant: the 50\u2010year challenge","volume":"3","author":"Gustafsson","year":"2004","journal-title":"Nature Rev Drug Discovery"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.thromres.2006.02.012","article-title":"Ximelagatran: an eulogy","volume":"118","author":"Boos","year":"2006","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0075","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure\u2010based design of novel potent nonpeptide thrombin inhibitors","volume":"45","author":"Hauel","year":"2002","journal-title":"J Med Chem"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0080","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1358\/dof.2003.028.04.729682","article-title":"Serine proteases as targets for antithrombotic therapy","volume":"28","author":"Ries","year":"2003","journal-title":"Drugs Future"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0090","first-page":"124","article-title":"Prevention of experimental venous thrombosis in rabbits with different low molecular weight heparins, dermatan sulphate and hirudin","volume":"25","author":"Matthiasson","year":"1995","journal-title":"Haemostasis"},{"issue":"Suppl. 1","key":"10.1111\/j.1538-7836.2007.02526.x_bb0095","first-page":"80","article-title":"Antithrombotic effects of recombinant hirudin in different animal models","volume":"21","author":"Just","year":"1991","journal-title":"Haemostasis"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0049-3848(98)00213-8","article-title":"Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat","volume":"94","author":"Elg","year":"1999","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0049-3848(02)00257-8","article-title":"Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats","volume":"107","author":"Carlsson","year":"2002","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0110","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/j.1538-7836.2006.02064.x","article-title":"A comparison of the \u00df\u2010D\u2010xysolside, odiparcil, to warfarin in a rat model of venous thrombosis","volume":"4","author":"Toomey","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2007.02526.x_bb0115","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1358\/dof.2005.030.09.938760","article-title":"Dabigatran\/Dabigatran etexilate","volume":"30","author":"Sorbera","year":"2005","journal-title":"Drugs Future"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2007.02526.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622102059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622102059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2007.02526.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:42:19Z","timestamp":1761532939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622102059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S1538783622102059"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02526.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02526.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}